Description of business GlaxoSmithKline 17 Compound Type Indication Phase MAA NDA Respiratory 159797 (TD 3327)** beta2 agonist asthma, chronic obstructive pulmonary disease (COPD) I 274150 selective iNOS inhibitor asthma, COPD I & allergic rhinitis 597901 beta2 agonist asthma & COPD I 681323 p38 alpha kinase inhibitor COPD (also RA) I 683699 (T-0047)** dual alpha4 integrin antagonist (VLA4) asthma & RA (also MS & IBD) I 766994 chemokine receptor 3 antagonist asthma & allergic rhinitis I 559090 alpha4 integrin antagonist asthma & allergic rhinitis II 685698 glucocorticoid receptor agonist asthma, COPD & allergic rhinitis II 842470 (AWD 12-281)** PDE IV inhibitor asthma, COPD & allergic rhinitis II mepolizumab (240563) anti-IL5 monoclonal antibody asthma & atopic dermatitis II Ariflo PDE IV inhibitor COPD Submitted 2004 S:Dec02 Non-CFC Metered Dose Inhaler propellants (106642) Serevent beta2 agonist asthma & COPD III 2004 N/A Flixotide/Flovent inhaled corticosteroid asthma & COPD Approved A:Apr97 AL:Dec02 Seretide/Advair beta2 agonist/inhaled corticosteroid asthma Approved A:Jun00 AL:Oct01 & Oct02 Diskus/Accuhaler (dry powder inhaler) Seretide/Advair beta2 agonist/inhaled corticosteroid adult & paediatric asthma – once daily dosing III 2005 2005 Seretide/Advair beta2 agonist/inhaled corticosteroid COPD Submitted S:Sep01 AL:Mar02 & Dec02 Serevent beta2 agonist COPD Approved 2003 A:Mar02 Hepatitis Vaccines Hepatitis E recombinant hepatitis E prophylaxis II Extra strength hepatitis B recombinant extra strength hepatitis B prophylaxis III 2003 TBD Twinrix 2 doses recombinant combined hepatitis A and B prophylaxis Approved A:Sep02 2003 (child/adolescent) Paediatric Vaccines Rotarix live attenuated – oral rotavirus prophylaxis II 2005 N. meningitidis conjugated meningitis prophylaxis II 2004 Meningitis B (Cuba) subunit meningitis B prophylaxis II TBD S. pneumoniae paediatric conjugated S. pneumoniae disease prophylaxis for children III 2005 MMR-varicella live attenuated measles, mumps, rubella and varicella prophylaxis III 2005 Infanrix/Pediarix PeNta- recombinant diphtheria, tetanus, pertussis, hepatitis B Approved A:Oct00 A:Dec02 HepB-IPV and inactivated polio prophylaxis Infanrix HeXa-Hep B- IPV/Hib conjugated/recombinant diphtheria, tetanus, pertussis, hepatitis B Approved A:Oct00 TBD and inactivated polio prophylaxis and Haemophilus influenzae type B prophylaxis Other Vaccines Dengue fever attenuated tetravalent vaccine prophylactic use I HIV recombinant HIV prophylaxis I New influenza subunit influenza prophylaxis – new delivery I S. pneumoniae elderly conjugated S. pneumoniae disease prophylaxis I Staphylococcal antibodies** monoclonal antibody prevention of staphylococcal infections I Epstein-Barr virus (EBV) recombinant EBV prophylaxis II Human papillomavirus (HPV) recombinant prophylaxis of HPV infections II Malaria recombinant malaria prophylaxis II Boostrix subunit adolescent/adult booster for diphtheria, tetanus Approved A:Oct00 2004 and pertussis Boostrix IPV subunit adolescent/adult booster for diphtheria, tetanus, III 2003 pertussis and inactivated polio Simplirix recombinant genital herpes prophylaxis III Pharmaccines GSK/PowderJect** recombinant hepatitis B treatment I 249553 recombinant treatment of lung cancer/melanoma II The content of the portfolio will change over time as new compounds progress from research to development and from development to the market. Owing to the nature of the drug development process, it is not unusual for some compounds, especially those in early stage of investigation, to be terminated as they progress through development. For competitive reasons, new projects in pre-clinical development have not been disclosed and some project types may not have been identified.

Previous Page | Next Page